Drug pricing in Taiwan is regulated by the National Health Insurance Administration (NHIA). New drugs are priced based on the average or lowest prices among ten reference countries, depending on classification. The NHIA also uses specific pricing formulas for generics and biosimilars, balancing affordability with innovation to ensure public access to essential medicines.